Citigroup Lowers Teladoc Health Target Price to $9.00.

Citigroup has maintained its 'Neutral' rating on Teladoc Health (TDOC) but lowered the target price from $10.00 to $9.00, a 10% decrease. The target price adjustment reflects Citigroup's ongoing evaluation of TDOC's potential growth. Historical ratings for TDOC have been diverse, with analysts offering varying assessments of the company's market value. The average target price for TDOC is $9.06, indicating a 21.22% upside from the current price. The average brokerage recommendation is 2.8, indicating a 'Hold' status.